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Abstract 248 words 
 
Recently, those substances deriving from the active ingredient of the Khat plant, 
cathinone, have been rising in popularity. Indeed, 4-methylmethcathinone 
(mephedrone; „Meow Meow‟ and others) has been seen by some as a cheaper 
alternative to other classified recreational drugs. We aimed here at providing a 
state-of-the-art review on mephedrone history and prevalence of misuse; 
chemistry; pharmacology; legal status; product market appearance; 
clinical/management; and related fatalities. Because of the limited evidence, 
some of the information here presented has been obtained 
from user reports/drug users‟ orientated websites. 
Most common routes for mephedrone recreational use include insufflation and 
oral ingestion. It elicits stimulant and empathogenic effects similar to 
amphetamine, methylamphetamine, cocaine and MDMA. Due to its 
sympathomimetic actions, mephedrone may be associated with a number of both 
physical and psychopathological side effects. Recent preliminary analysis of 
recent UK data carried out in 48 related cases have provided positive results for 
the presence of mephedrone at post mortem.  
Within the UK, diffusion of mephedrone may have been associated with an 
unprecedented combination of a particularly aggressive online marketing policy 
and a decreasing availability/purity of both ecstasy and cocaine. Mephedrone 
has been recently classified in both the UK and in a number of other countries as 
a measure to control its availability. Following this, a few other research 
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psychoactives have recently entered the online market as yet unregulated 
substances that may substitute for mephedrone. Only international collaborative 
efforts may be able to tackle the phenomenon of the regular offer of novel 
psychoactive drugs. 
 
 
 
Key words: mephedrone; meow meow; cathinones; drug misuse; drug related 
deaths; psychoactive drugs. 
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INTRODUCTION 
 
Mephedrone (4-methylmethcathinone;  „Plant Food‟, „Meow Meow‟, „Miaow‟, 
„Drone‟, „Meph‟, „Bubbles‟, „Spice E‟, „Charge‟, „M-Cat‟, „Rush‟, „Ronzio‟, „Fiskrens‟ 
and „MMC Hammer‟) is the most popular of the cathinone derivatives, which also 
include butylone; methylone, and remaining compounds (ACMD 2010; Morris 
2010). It has been readily available for purchase both online and in head shops 
and its circulation has been promoted by aggressive web-based marketing 
(Deluca et al, 2009; Mephedrone2you 2010; National Treatment Agency 2010). 
Mephedrone is a psychoactive research chemical that elicits stimulant and 
empathogenic effects similar to amphetamines, methylamphetamine, cocaine 
and MDMA (Winstock et al 2010a). It has drawn wider attention from the media 
since it has been allegedly linked to a number of fatalities. As we write, only few 
formal papers and experimental/clinical data have been published (Dargan et al 
2010; Winstock et al 2010a; Winstock et al 2010b). Some of the information 
contained in this review has been obtained from user reports and drug 
users‟ orientated websites, again highlighting the lack of peer reviewed 
resources. Given the limited information available, we aimed here at providing a 
state-of-the-art review on mephedrone chemical, pharmacological and clinical 
issues. 
 
HISTORY AND PREVALENCE OF MISUSE 
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In 1929, Saem de Burnaga Sanchez first described the synthesis of 
mephedrone. However, khat-extracted cathinones first appeared in Israel in early 
2000‟s, locally named as „Hagigat‟ (Urquhart 2009), eventually outlawed following 
a large number of hospitalisations caused by its exposure (Bentur 2008). As a 
result of the ban, chemists began altering the chemical structure of cathinone to 
synthesize related unscheduled compounds. First online reference to 
mephedrone reportedly occurred in May 2003 (Power 2009), but both its 
availability for online purchase (Camilleri et al 2010; Roussel et al 2009) and 
related popularity (Deluca et al 2009) started in 2007. Data collected by the 
European Monitoring Centre for Drugs and Drug Addiction show that over the 
first quarter of 2010 there have been detections in some 20 EU Member States, 
with most of them reporting small to medium-size seizures (Europol-EMCDDA 
2010).  
Although not well known in the USA, 4-methylmethcathinone appears to be 
particularly popular in the UK (Brandt et al 2010a; Mephedrone2you 2010). 
During the second quarter of 2009, the Forensic Science Service received 
submissions of three times as many samples of mephedrone for analysis than it 
had in the previous 12-month period (ACMD 2010; Ghodse et al 2010). Since 
mephedrone appeared only very recently on the market, it does not feature in 
most drug use household surveys, and it is uncertain how many people present 
with a history of mephedrone misuse. Most available data originate from self-
reported surveys and small focus group research. Main settings of use might be 
nightclubs, parties and people‟s home (Newcombe 2009). A research project led 
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by the National Addiction Centre in London with 2,295 readers of the dance 
magazine „Mixmag‟ disclosed that 41.7% of surveyed people had ever tried 4-
methylmethcathinone and 33.2% had used during last month, making it the sixth 
most popular drug among clubbers, after tobacco, alcohol, cannabis, ecstasy and 
cocaine. Cathinone derivative methylone was mentioned as well in the survey 
(Winstock et al, 2010b). Dargan et al (2010) assessed both prevalence and 
frequency of use of mephedrone. Data was collected using a questionnaire 
survey in schools, colleges and universities in the Tayside area of Scotland in 
February 2010. Some 1006 individuals completed the survey and 205 (20.3%) 
reported previous use of mephedrone; 23.4% reported using only using 
mephedrone on one occasion previously, and 4.4% reported daily use. A total of 
48.8% of users sourced mephedrone from street level dealers and 10.7% from 
the Internet.  Although both the Mixmag and Scottish schools surveys are limited 
by the nature of sampling technique and target populations, the heightened 
interest in mephedrone (National Treatment Agency 2010) might be readily 
testified by the rise in number of both telephone inquiries and visits to both the 
TOXBASE and FRANK websites (ACMD 2010).   
Mephedrone appearance on the UK market may have been associated with an 
unprecedented decreasing purity of both MDMA and cocaine (Hand and Rishiraj 
2009; Fleming 2010; Measham et al 2010; National Treatment Agency 2010). 
Similar observations have been recently reported from the Netherlands (Brunt et 
al, 2010). As a consequence, drug users may have switched to mephedrone, 
being allegedly cheaper and more powerful than the currently available 
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„traditional‟ stimulants (Deluca et al 2009). Moreover, recent changes in the 
attitudes of drug users, as well information-sharing and marketing through the 
Internet, are likely to have played a significant role. Ready availability of 
mephedrone may well have boosted its diffusion and prior to its ban many 
surveyed people thought 4-methylmethcathinone not to be harmful because of its 
appealing legal status (Daly 2010; Ramsey et al 2010). This combination of 
circumstances has been massively capitalized on by suppliers who may 
conceivably have made huge profits by promoting the drug through an 
aggressive e-commerce advertising policy and by arranging a widespread 
delivery system (Power 2010; Freepressindex 2010; Mephedrone2you 2010). 
Paradoxically, online newspaper articles about mephedrone contained banners 
pointing towards drug vendors and some editorialists have indicated mephedrone 
as an example of the future of drug dealing (Power 2009). One could also 
wonder about the possible role the media has played in promoting mephedrone 
use (Davey et al 2010). From this point of view, Measham and colleagues (2010) 
have referred to the conceptualization of mephedrone in the media as a „moral 
panic‟, and as such this may have obscured the potential for accurate and 
valuable safety information to be transmitted and received on a large scale. 
Immediately after the mephedrone ban, novel compounds have already 
appeared on the horizon, with molecules such as naphyrone (also known as 
naphthylpyrovalerone, „Energy 1‟ or „NRG-1‟) and MDAi (5,6-methylendioxy-2-
aminoindane) representing two of the emerging research chemicals set to 
replace mephedrone as alternative psychoactives. In fact, they are marketed and 
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advertised with modalities similar to those referring to mephedrone up to a few 
months ago (Townsend 2010). Interestingly, some of these products have been 
shown to contain mephedrone and/or MDPV (Methylenedioxypyrovalerone; 
Brandt et al 2010b). 
 
 
CHEMICAL CHARACTERISTICS: 
 
Mephedrone is a semi-synthetic compound belonging to the chemical class of 
cathinone derivatives (or substituted cathinones). Cathinone is a natural 
amphetamine-like alkaloid found in the fresh leaves and stems of the African 
shrub Catha edulis (Khat; Kalix 1992). The systematic name of mephedrone is 2-
(methylamino)-1-(p-tolyl)propan-1-one(2S)-2-(methylamino)-1-(4-
methylphenyl)propan-1-one, in accordance with the International Union of Pure 
and Applied Chemistry (IUPAC). Different acronyms include 1-(4-methylphenyl)-
2-methylaminopropan-1-one, 2-methylamino-1-p-tolylpropan-1-one, 4-
methylmethcathinone, 4-MMC, and MMCAT. The molecular formula and mass 
are C11H15NO and 177.242 g/mol, respectively (Chemspider 2010; Kalix 1992; 
Pubchem 2010). The structure of mephedrone is shown in Figure 1 where it 
differs from cathinone by methylation of the amino group and the benzene ring 
present (Gustaffson and Escher 2009; Osorio-Olivares et al 2003). The 
cathinones are beta keto derivatives of phenethylamines (Figure 1), and hence 
analogues of amphetamines (Chemspider 2010). Since they are mainly synthetic 
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in origin, beta-keto amphetamines are also known as „bk designer drugs‟. 
Each of the phenethylamine compounds has a parallel cathinone analogue. For 
example, methcathinone is the cathinone anologue of methylamphetamine 
(ACMD 2010).  
 
--------------------------------------------------------------------------------------------------------- 
Pls include about here  
Figure 1. Mephedrone and related structures 
--------------------------------------------------------------------------------------------------------- 
 
Like other cathinone derivatives, mephedrone possesses a single chiral centre 
thereby existing in two enantiomeric forms, (S)- and (R)-mephedrone (Europol-
EMCDDA 2010; Gibbons and Zloh 2010). For cathinone, the S(-) form is more 
potent than the R(-) enantiomer, and this may be similar for mephedrone. The 
synthesis of (S)-4-methylcathinone, an (S)-mephedrone precursor, has been 
carried out via Friedel-Crafts acylation as shown in Figure 2 (Osorio-Olivares et 
al 2003) 2). Further methylation of the amino group would yield (S)-mephedrone. 
 
--------------------------------------------------------------------------------------------------------- 
Pls include about here  
Figure 2. Stereoselective synthesis of (S)-4-methylcathinone 
--------------------------------------------------------------------------------------------------------- 
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It is relatively easy to produce mephedrone in non-professional laboratories 
(Figure 3) via bromination of 4-methylpropiophenone followed by reaction with 
methylamine or by oxidation of 4-methylephedrine (Archer 2009; Europol-
EMCDDA 2010). Both reactions would result in a mixture of R- and S- 
mephedrone. However, a stereoselective synthesis in the latter is possible using 
a single enantiomeric form (Lee et al 2007) of 4-methylephedrine (Europol-
EMCDDA 2010).  
 
--------------------------------------------------------------------------------------------------------- 
Pls include about here 
Figure 3. Synthesis of mephedrone 
--------------------------------------------------------------------------------------------------------- 
 
 
PHARMACOLOGY 
 
Some cathinone derivatives are currently under active research as a promising 
class of monoamine uptake inhibitors (Meltzer et al 2006). However, only little is 
known about the pharmacology of 4-methylmethcathinone. Given cathinone 
derivatives affiliation to beta-ketoamphetamines, mephedrone is expected to act 
as a central nervous system stimulant by promoting the release of monoamine 
neurotransmitters and likely inhibiting their reuptake (Kalix 1990; Feyiisa and 
Kelly 2008). Indeed, in vitro studies on the effects of the cathinone derivatives 
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methcathinone and methylone confirm that the main mechanism of action is very 
similar to that of amphetamine, therefore being characterized by a predominant 
action on plasma membrane catecholamine transporters (Cozzi et al, 1999). Both 
amphetamines and cathinones bind to noradrenalin, dopamine and serotonin 
transporters (Nagai et al 2007), each of them differing from each other by its 
relative binding potency. In particular, the presence of the ring substituent on the 
phenethylamine core modifies the pharmacological properties by giving the 
compound some MDMA-like effects, whereas amphetamines and cathinone 
derivatives without ring substituents exert mostly stimulant effects (Europol-
EMCDDA 2010). Cathinones‟ potencies are mostly lower than those of 
amphetamines, as beta-keto amphetamines show a reduced ability to cross the 
blood-brain barrier due to the presence of the beta group (Nagai et al 2007; Gygi 
et al 1996).  
N-demethylation to the primary amine, reduction of the keto moiety to the 
respective alcohol, and oxidation of the tolyl moiety to the corresponding alcohols 
and carboxylic acid is the major metabolic pathway for mephedrone, followed by 
N-dealkylation. Intake of both mephedrone and other beta-keto-amphetamines 
can be detected with appropriate urine testing technology (Meyer et al 2010; 
Zaitsu et al 2009). 
 
 
LEGAL STATUS  
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At the time of writing, mephedrone is not under a consistent international control. 
In fact, misuse of mephedrone has spread very quickly in a relatively short period 
of time, notably arising in popularity among drug users (see Table 1; under 
supplementary material). In the UK, where mephedrone has been greatly 
drawing both mass media and Government attention, the Advisory Council on the 
Misuse of Drugs has published a report on the cathinone derivatives, 
recommending their inclusion in the Misuse of Drugs Act 1971 under Class B. As 
a result, mephedrone was made a controlled drug (class B) on the 16th April 
2010 (ACMD, 2010). It may be of interest that control in some countries (e.g. 
Finland) has been by use of legislation other than the Misuse of Drugs Act or 
equivalent measures (see Table 1; under supplementary material).  
Although in a way similar to many other recreational drugs 4-
methylmethcathinone has been specifically synthesized to avoid existing drug 
misuse laws (BBC News 2009; Deluca et al 2009; Financiarul online 2010), many 
synthetic „legal highs‟ may not be legal. In fact, active ingredients in legal highs 
purchased from Internet-based suppliers do not remain consistent over time, 
hence increasing the risk of individuals purchasing a „legal high‟ that contains a 
controlled drug (Ramsey et al, 2010). Furthermore, even if they have no history 
of previous use as drugs, specific psychoactive substances may still be liable to 
control under the Medicines Act. However, labelling is likely to be the key to 
better understand the phenomenon. In fact, a number of recreational 
psychoactive drugs available for online purchase, including mephedrone, are 
claimed to be „plant feeders‟, „bath salts‟ and „not for human consumption‟ 
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(Mephedrone2you 2010), and prosecution as such may be difficult (Winstock and 
Ramsey, 2010).  Many online suppliers‟ sites implicitly however suggest its use 
as a drug, referring to the rave and party culture in the website graphic design 
and/or providing the customers with ambiguous reviews written by self-styled 
gardeners (Mephedrone.com 2010). It is of concern that, despite the banning of 
mephedrone, little may indeed prevent suppliers from using the same marketing 
approach for novel and shortly forthcoming compounds (Brandt et al 2010a).  
Finally, it is worth noting that in March 2010 the EMCDDA and Europol submitted 
a joint report on mephedrone (Europol-EMCDDA 2010) to the Council of the EU, 
the European Commission and the European Medicines Agency (EMA), 
presenting the case for the forthcoming formal risk assessment of the drug.  
 
MARKET AND COMMERCIAL APPEARANCE  
 
Mephedrone occurs as a white, sometimes off-white or slightly yellowish, powder 
or fine crystals. Less frequently, it is marketed as capsules or tablets of various 
colours, shape, and thickness, with or without a logo. Although mainly sold in 
powder and crystal forms, mephedrone may be commercially available in tablets 
and included within vegetable-based capsules. It has been reported that 
mephedrone is sometimes sold in some countries as either ecstasy or cocaine 
(Deluca et al 2009; ABC News 2008). Furthermore, it may be found to be mixed 
with some adulterants, such caffeine, paracetamol and even cocaine, 
amphetamine and ketamine (Camilleri et al 2010). 
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ROUTES OF ADMINISTRATION; DOSAGE; USE IN COMBINATION WITH 
OTHER DRUGS 
 
Most common routes for recreational use include insufflation (snorting) and oral 
ingestion. Because of its solubility in water, mephedrone is reportedly used by 
rectal administration (dissolved in an enema or within gelatine capsules) as well, 
or injected intravenously. Insufflation is likely to be the most common modality. 
When snorted, mephedrone elicits its effects within a few minutes, with the peak 
being reached in less than 30 minutes followed by a rapid comedown. According 
to online users‟ advice, mephedrone dosage for snorting may range between 
25mg and 75mg, with the lower threshold being at 5-15mg and with a level in 
excess of 90mg to be considered a high dosage (Sumnall and Wooding 2009). 
Dosing is more frequent when taken intranasally; this route is allegedly  
associated with greater abuse liability than the oral route (Winstock et al, 2010). 
Other typical methods of intake include oral administration, through ingestion of 
capsules or tablets; swallowing mephedrone powder wrapped up in cigarette 
paper („bombing‟); or mixed with water. On average, the most common oral 
dosages are higher than the snorting ones (Sumnall and Wooding 2009), being 
in the range between 150mg and 250mg. Time of onset may be of 45 minutes-2 
hours, and may vary in association with the amount of food contained in the 
stomach. Because of this, users suggest to take mephedrone on an empty 
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stomach. With oral administration, psychoactive effects may last longer (up to 2-4 
hours); side effects might be milder and the urge to re-dose less pressing. Some 
consumers exploit both insufflation and oral ingestion in combination to achieve 
both faster onset and long-lasting effects (Deluca et al 2009). With respect to oral 
ingestion, users report that rectal administration is characterized by faster onset 
of the effects and requires lower doses, e.g. 100mg on average (Deluca et al 
2009).  
Although not typically advised, because this may increase the drug addictive 
liability levels (Deluca et al 2009), mephedrone may also be injected either 
intramuscularly (Wood et al, 2010a) or intravenously (IV), at 1/2 or 2/3 of the oral 
dose (Deluca et al 2009). This method of intake appears to be fairly well known 
in Romania, where mephedrone may be combined with heroin (Europol-
EMCDDA 2010). Because of the capability of the drug to induce tolerance upon 
repeated doses, an increasing number of users reports have stated a quick 
progression to either regular drug use and/or uncontrolled bingeing behaviour 
(known as „fiending‟), with 1-4 grams of mephedrone consumed in a session to 
prolong the duration of its effects (Deluca et al 2009; Europol-EMCDDA 2010). A 
recent survey carried out by a drug-related website has unveiled an average 
monthly use of 11.16 grams for each mephedrone consumer (Drugsforum 2010). 
Although withdrawal symptoms are not typically reported, users often describe 
strong cravings for the drug (Newcombe 2009). In a survey carried out in 
Scotland in February 2010, roughly 1 out of 6 users‟ surveyed reported 'addiction 
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or dependence' symptoms associated with their mephedrone use (Dargan et al 
2010). 
Although one could argue about the limited generalizability of most studies here 
quoted and of the advice provided from online fora, according to web users 
mephedrone may be taken in combination with a number of stimulants, sedatives 
and psychedelics (Deluca et al 2009). These may include: cocaine; 
amphetamine; modafinil; butylone; MDPV; methylone; metamfepramone; alcohol; 
GBL/GHB; benzodiazepines; kratom (mytraginin); heroin; cannabis; ketamine 
(with this combination being known as „challenge‟); MDMA; BZP; TFMPP; DMAA; 
and sildenafil. One could conclude that the above combinations are likely to 
increase mephedrone toxicity effects and harm potential.  
 
DESIRED AND UNTOWARD MEPHEDRONE EFFECTS  
 
Mephedrone effects have been variously compared by users to those of cocaine, 
amphetamine and MDMA. Self-reported subjective effects may include (Winstock 
et al 2010b; Deluca 2009): 
 
- Intense stimulation and alertness, euphoria 
- Empathy/feelings of closeness, sociability and talkativeness 
- Intensification of sensory experiences 
- Moderate sexual arousal 
- Perceptual distortions (reported with higher dosages only) 
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According to Dargan et al (2010), some 56% of those who had used mephedrone 
may complain of at least one unwanted effect associated with its use; these may 
include (ACMD 2010; Deluca 2009; James et al, 2010; Wood et al 2009; Wood et 
al 2010b):  
 
- Gastrointestinal system: Loss of appetite, dry mouth, nausea, vomiting 
and stomach discomfort 
- Central nervous system/neurological: Tremors, tense jaws, trismus, 
bruxism, mild muscle clenching, stiff neck/shoulders, headache (very 
common), dizziness/light-headedness, tinnitus, seizures, nystagmus, pupil 
dilation, blurred vision, numbness of tactile sensitivity (reported at higher 
dosages) 
- Central nervous system/psychiatric: Anxiety, agitation, confusion, 
dysphoria, irritability, aggression; depression, lack of motivation, 
anhedonia; time distortions, long-lasting hallucinations, paranoid 
delusions, short term psychosis, short term mania; insomnia and 
nightmares; impaired short term memory, poor concentration, mental 
fatigue. Psychopathological consequences are more frequently reported if 
the drug is taken at higher dosages/in prolonged sessions (Deluca 2009; 
Winstock et al 2010b) and/or if the misuser presents with an underlying 
psychobiological vulnerability (Odenwald et al 2005; Odenwald et al 
2009). 
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- Cardiovascular system: Tachycardia, elevated blood pressure, respiratory 
difficulties, chest pain and elevated blood pressure, peripheral 
vasoconstriction. Possibly due to vasoconstriction, users have anecdotally 
described cold/blue fingers  
- Renal/urinary excretory system: Difficulties in urination, possible 
nephrotoxicity, anorgasmia 
- Miscellaneous: Changes in body temperature regulation, with hot flushes 
and sweating (so called „mephedrone sweat‟, characterized by a strong 
body odour); painful nasal drip, nose and throat bleeds with burns and 
ulcerations (following insufflation); immunological toxicity (vasculitis, 
infections and ulcerations) 
  
Most of the above untoward effects seem to be similar to those already 
documented for amphetamine, methamphetamine and MDMA (Schifano et al 
2010), implicitly supporting a sympathomimetic activity of mephedrone. 
Conversely, symptoms of depression and anhedonia could be tentatively 
associated to a putative depletion of serotonin and dopamine as a consequence 
of drug use (ACMD 2010), similarly to what may occur with other stimulants 
(Schifano 1996). It is impossible to determine a „safe‟ dose for mephedrone, 
since negative side effects may present in association with any dosage taken. 
Furthermore, similar dosages may have dramatically different consequences in 
different individuals (Dickson et al 2010).  
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TREATMENT and MANAGEMENT 
 
Acute management of adverse events 
The only available information relating to treatment of mephedrone acute 
behavioural toxicity derives from observations carried out in an Emergency 
Department in central London. In most cases, the mephedrone-related agitation 
was treated with benzodiazepines. All 15 patients were discharged after 
appropriate observation with no sequelae (Wood et al 2009; Wood et al 2010). 
Since no guidelines have yet been specifically provided, treatment is to be 
considered empirical.   One could argue that the treatment for the more life-
threatening conditions might be broadly similar to that of amphetamine poisoning. 
Those individuals presenting with less severe symptoms should be assessed and 
managed as for any other users of psychoactive drugs and may simply need 
reassurance, support and observation. People with underlying cardiac, 
neurological, and psychiatric conditions, especially those on medication, are 
likely to be at greatest risk of serious adverse events (Winstock et al, 2010a). 
 
Longer term therapeutic psychological and harm reduction approaches  
Harm reduction advice has been provided by pro drug websites, including using 
the drug not exceeding 500mg per session and dosing orally rather than 
insufflating (Newcombe 2009). Since too little is known about mephedrone 
potential neurotoxicity or long term consequences of its use, only commonsense 
advice about the use of any psychoactive stimulant has been provided (Winstock 
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et al 2010a). This may include: avoiding regular use to avoid developing 
tolerance; not using the drug in combination with other stimulants or large 
amounts of alcohol and other depressants; not injecting the drug; remaining well 
hydrated when using the drug; and avoiding becoming overheated. Both a brief 
motivational intervention and appropriately adapted psychosocial intervention 
have been suggested to treat mephedrone addiction (Winstock et al 2010a).  
 
 
MEPHEDRONE RELATED DEATHS 
 
During the last few months, British media and newspapers have been reporting 
about fatalities allegedly related to mephedrone consumption almost on a weekly 
basis, but only a proportion of them have already been confirmed. A report on a 
mephedrone-related fatality first appeared in Sweden, referring to an 18-years-
old female death which occurred in December 2008. No other drugs, apart from 
mephedrone, were identified by the toxicological screenings (Gustaffson and 
Escher 2009). Previously, a Danish teenager found in possession of mephedrone 
died in May 2008, although toxicology reports were inconclusive (Campbell 
2009). Published data regarding the first mephedrone-related death in the USA 
involved the combined use of mephedrone and heroin (Dickson et al 2010). 
Data collected by the National Programme on Substance Abuse Deaths (Ghodse 
et al 2010) suggest that by the beginning of October 2010 there have been 45 
suspected deaths related to mephedrone in England, 12 of in Scotland, 1 in 
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Wales, 1 in Northern Ireland and 1 in Guernsey. Preliminary analysis carried out 
in 48 out of these 60 cases has provided positive results for the presence of 
mephedrone at post mortem. Remaining cases are, to date, awaiting further 
investigation. It is important to emphasize that a number of fatalities reported to 
the np-SAD implicated mephedrone consumption in combination with other 
substances/other recreational drugs, such as alcohol, cannabis, cocaine, 
amphetamine, methadone, methylone and 4-MTA.  
 
 
CONCLUSIONS 
 
This paper may represent a comprehensive and critical review of the currently 
available information on the novel psychoactive drug 4-methylmethcathinone. 
Data have been collected from the very few published articles in scientific peer- 
reviewed journals, from official bodies‟ reports, and from the users‟ grey 
literature/pro drug websites. It is worth emphasizing the importance of the latter, 
since mephedrone was indeed first identified by the Psychonaut Web Mapping 
project (Deluca et al 2009) whilst examining new trends in drug use by actively 
monitoring drug users‟ orientated websites.  
Although pharmacodynamics data are currently uncertain and further data from 
peer reviewed studies are needed, effects of 4-methylmethcathinone are 
reported to be broadly similar to those of MDMA/ecstasy and cocaine. In fact, 
mephedrone may feature mainly stimulant-like effects, such as mood 
enhancement and alertness, but possesses as well both empathogenic and 
22 
 
hallucinogenic properties at higher dosages. Only a few related case reports 
have been published so far, and there is a distinctive lack of information about 
the acute and chronic toxicity of 4-methylmethcathinone. In the UK, mephedrone 
has been tentatively associated with a number of deaths. However, most of them 
may have been reported by the popular press with some levels of inaccuracy, 
and this is likely to have generated confusion in the general public (Davey et al 
2010). Preliminary data from the np-SAD here commented emphasize the need 
of continuing to monitor mephedrone. In fact, because of the recent appearance 
of the drug into the market, and the lack of mephedrone knowledge on the 
coroners‟ side, one could still think that the number of related fatalities has been 
under reported. It is worth noting that, after ban legislation came into effect, post-
mortem samples taken in June 2010 in the UK have still tested positive for 
mephedrone (Ghodse et al 2010; Davies et al 2010).  
A large quantity of personal advice and suggestions with respect to mephedrone 
dosage, best ways of experimenting with its effects and avoiding untoward 
reactions was here largely available in the websites we sampled. The technical 
knowledge on new products entering the market, hardly obtained through 
reference books and scientific journals, is often held in closed groups of users, 
who exchange online information with each other without any contact with the 
scientific world (Littlejohn et al 2005; Schifano et al 2006; Schmidt et al in press). 
Much of the material quoted here referring to web based sources was however 
not evidence-based and, for this reason, has proved to be difficult indeed to 
critically evaluate. In particular, we did not have any possibility to confirm if the 
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substance the misusers were referring to was indeed mephedrone. We did not 
survey here the actual use of the online information by interested web surfers, 
but only the availability and the content of data on mephedrone.  
Future studies should better assess both the acute and chronic toxicity of 
mephedrone and related cathinone derivatives. With a better understanding of 
these drugs‟ clinical pharmacology, it is hopeful that related clinical management 
levels will improve. Furthermore, the characteristics of those consumers who 
take advantage of the online available information on mephedrone and similar 
compounds should be better assessed and, as a result, the stereotypical image 
of the „drug misuser‟ may need to change (Littlejohn et al, 2005). Finally, the 
potential of innovative ICT prevention programmes for novel psychoactive 
compounds, such as the EC-funded 2010-2012 ReDNet research project 
(www.rednetproject.eu; Corazza et al in press) remains to be tested. 
Mephedrone has been recently classified in both the UK and in a number of other 
countries as a measure to control its diffusion. One could argue that the designer 
drugs market appears to be constantly one step ahead of the authorities. 
Although it is beyond the scope of this paper to comment on the effectiveness of 
these control measures, it is a matter of fact that a few psychoactive compounds 
(e.g.: NRG-1; NRG-2; MDAi; MDPV etc) have recently entered the online market 
as substitutes for mephedrone. It is our opinion that only international 
collaborative efforts may be able to tackle the phenomenon of the regular offer of 
novel psychoactive drugs. 
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Figure 2. Stereoselective synthesis of (S)-4-methylcathinone 
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Figure 3. Synthesis of mephedrone 
 
 
